A

Amneal Intermediate Inc
NASDAQ:AMRX

Watchlist Manager
Amneal Intermediate Inc
NASDAQ:AMRX
Watchlist
Price: 8.46 USD -2.76% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
Amneal Intermediate Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one AMRX stock under the Base Case scenario is 18.41 USD. Compared to the current market price of 8.46 USD, Amneal Intermediate Inc is Undervalued by 54%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AMRX Relative Value
Base Case
18.41 USD
Undervaluation 54%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

1.1
P/S
P/S
Price to Sales
1.1
vs History
3
vs Industry
71
Median 3Y
0.6
Median 5Y
0.7
Industry
2.5
Forward
0.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
1
Median 3Y
-5.5
Median 5Y
-4.7
Industry
22.3
Forward
13.9
More Details
7.6
P/OCF
P/OCF
Price to OCF
7.6
vs History
19
vs Industry
42
Median 3Y
6
Median 5Y
5.7
Industry
17.4
More Details
39.8
P/FCFE
P/FCFE
Price to FCFE
39.8
vs History
15
vs Industry
15
Median 3Y
10.6
Median 5Y
-1.2
Industry
24.4
More Details
132.4
P/B
P/B
Price to Book Value
132.4
vs History
3
vs Industry
0
Median 3Y
3.9
Median 5Y
4.3
Industry
2.1
More Details
2.2
EV/S
EV/S
Enterprise Value to Sales
2.2
vs History
19
vs Industry
51
Median 3Y
1.8
Median 5Y
1.9
Industry
2.7
Forward
1.8
More Details
6.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.1
vs History
34
vs Industry
37
Median 3Y
4.9
Median 5Y
5.3
Industry
5.3
More Details
10.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.3
vs History
36
vs Industry
34
Median 3Y
8.6
Median 5Y
9.2
Industry
13.6
Forward
8.2
More Details
18.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
18.9
vs History
55
vs Industry
25
Median 3Y
17.5
Median 5Y
19.8
Industry
16.9
Forward
8.8
More Details
15
EV/OCF
EV/OCF
Enterprise Value to OCF
15
vs History
60
vs Industry
29
Median 3Y
17.6
Median 5Y
16.9
Industry
15.7
More Details
18.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18.8
vs History
50
vs Industry
22
Median 3Y
19.1
Median 5Y
19
Industry
18.8
More Details
1.6
EV/IC
EV/IC
Enterprise Value to IC
1.6
vs History
3
vs Industry
45
Median 3Y
1.3
Median 5Y
1.3
Industry
2
More Details

Multiples Across Competitors

AMRX Competitors Multiples
Amneal Intermediate Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Amneal Intermediate Inc
NASDAQ:AMRX
2.6B USD 1.1 -31.2 10.3 18.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
871.6B USD 22.4 118.7 59.3 66.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.6T DKK 14 40.1 26.7 30.7
US
Johnson & Johnson
NYSE:JNJ
395.9B USD 4.5 27 13 16.8
US
Merck & Co Inc
NYSE:MRK
278.3B USD 4.5 20.3 13.7 16.8
CH
Roche Holding AG
SIX:ROG
216.5B CHF 3.7 18.8 10.6 12.5
UK
AstraZeneca PLC
NASDAQ:AZN
241.9B USD 4.9 37.6 17.2 25.8
CH
Novartis AG
SIX:NOVN
197.5B CHF 4.7 14.1 11.1 16.5
US
Pfizer Inc
NYSE:PFE
165.9B USD 3 -63.9 12.8 20.8
P/E Multiple
Earnings Growth
US
A
Amneal Intermediate Inc
NASDAQ:AMRX
Average P/E: 39.5
Negative Multiple: -31.2 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
118.7
425%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
40.1
90%
US
Johnson & Johnson
NYSE:JNJ
27
-22%
US
Merck & Co Inc
NYSE:MRK
20.3
7 419%
CH
Roche Holding AG
SIX:ROG
18.8
30%
UK
A
AstraZeneca PLC
NASDAQ:AZN
37.6
175%
CH
Novartis AG
SIX:NOVN
14.1
19%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -63.9
712%

See Also

Summary
AMRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
AMRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AMRX stock valuation using valuation multiples.
Wall Street Estimates
AMRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AMRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 188,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.